Kanilad

Lacosamide, the active ingredient in Kanilad, is a sodium channel blocker presented as an oral dosage form for oral use. It is indicated for the treatment of focal onset (partial‑onset) seizures in patients with epilepsy.

GNH USA supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation to support import, distribution and clinical use across multiple markets. GNH USA's global network ensures reliable logistics and timely delivery to meet the needs of healthcare providers.

Lacosamide is an antiepileptic drug that acts on sodium channels to control seizure activity.

- Focal onset seizures: reduces seizure frequency in patients with epilepsy. - Adjunctive therapy in epilepsy: added when monotherapy does not achieve adequate control. - Partial‑onset seizures with secondary generalization: helps prevent spread of seizure activity.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate pain in the head.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: thoughts of self‑harm requiring immediate medical attention.

Before initiating therapy, clinicians should consider several safety factors.

- Renal impairment: evaluate kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. - Pregnancy: safety data are limited; use only if potential benefit justifies the risk. - Concomitant CNS depressants: observe for enhanced sedation or respiratory depression. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Other sodium‑channel blockers (e.g., carbamazepine): risk of additive CNS depression. - Drugs that affect cardiac conduction (e.g., digoxin): may exacerbate PR‑interval prolongation.

Moderate Interactions (Monitor Closely): - Carbamazepine: may reduce lacosamide effectiveness. - Phenytoin: may increase lacosamide clearance, lowering exposure. - Alcohol: can intensify dizziness and sedation.